cancer vaccine

MimiVax's glioblastoma vaccine misses primary endpoint in ph. 2

Long-term survival analysis shows approximately 42% of SurVaxM-treated patients 65 and under were alive through 30 months with no deaths at 54 months.

Marissa Russo Oct 7, 2026 8:00am

Graphic portrayal of a cancer vaccine releasing therapeutic material that latches onto tumors

Have Moderna, Merck kicked off a 'personalized med revolution'?

Sep 11, 2026 9:00am

Comedy and tragedy masks on red curtain background

BioNTech, Genentech cancel ph. 2 test of personalized cancer vax

Aug 28, 2026 1:50pm

Merck-Moderna vaccine data spur talk of Keytruda-like impact

Aug 20, 2026 9:25am

Merck-Moderna cancer vax slows recurrence in ph. 3 trial

Aug 19, 2026 6:45am

Boehringer bags viral vector platform for cancer vaccine R&D

Jul 7, 2026 10:35am